Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

RecruitingLast updated: 10 July 2026

FORAGER-2: This study is testing whether a new medicine called vepugratinib, when added to standard treatment, can help people with advanced or metastatic bladder cancer compared to a placeboA Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

Trial purpose

Medical clipboardCancer treatment

Tumor type

Urinary System Cancers Genitourinary

Age

People18+

Trial acronym

FORAGER-2

Clinical summary

Summary

You may be eligible if you have unresectable, locally advanced, or metastatic urothelial cancer, have a FGFR3 genetic alteration and have not had prior treatment for your advanced diesease. Prior treatment for an earlier stage disease is permitted. 

The study includes a safety lead-in phase to evaluate the combination of vepugratinib, enfortumab vedotin, and pembrolizumab.

Once the safety and tolerability of this combination is confirmed, participants are then randomly assigned (by chance) to one of two treatment arms to receive either:

  • Vepugratinib, enfortumab vedotin, and pembrolizumab
  • Placebo, enfortumab vedotin, and pembrolizumab

Study participation could last up to approximately 6 years.

 

Conditions

This trial is treating people with urothelial cancer that is locally advanced, metastatic or unable to be removed with surgery and has an FGFR3 gene mutation

Eligibility

Inclusion

  • Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present.
  • Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer.
  • Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Have adequate laboratory parameters

Exclusion

  • Have received prior systemic therapy for locally advanced or metastatic urothelial cancer (mUC).
  • Have any unresolved toxicities greater than Grade 1 Common Terminology Criteria for Adverse Events ([CTCAE] version 5.0) from prior neoadjuvant or adjuvant systemic therapy.
  • Have ongoing sensory or motor neuropathy of Grade 2 or higher
  • Have untreated or uncontrolled central nervous system (CNS) involvement or any history of leptomeningeal disease.
  • Current evidence corneal keratopathy or retinal disorder confirmed by ocular examination at screening.

Inclusion

  • Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
  • Your cancer has not spread to other parts of the body, but it is not possible to perform surgery to remove it (unresectable).
  • You are able to swallow medication by mouth.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ClinicalTrials.gov, EU Clinical Trials Register *. View further details about this trial on the registry via the links below:

Trial sponsor

Eli Lilly and Company

Scientific Title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

Trial added to VCTL (data sourced from registry): October 2025
Trial information last reviewed by VCTL: April 2026

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information